Medicenna Therapeutics (TSE:MDNA) Reaches New 12-Month Low – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price hit a new 52-week low on Tuesday . The company traded as low as C$0.47 and last traded at C$0.48, with a volume of 287813 shares trading hands. The stock had previously closed at C$0.54.

Medicenna Therapeutics Stock Down 13.0%

The company has a market cap of C$39.21 million, a price-to-earnings ratio of -3.13 and a beta of 2.90. The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30. The firm’s fifty day moving average price is C$0.65 and its 200-day moving average price is C$0.95.

Medicenna Therapeutics (TSE:MDNA) last announced its quarterly earnings results on Thursday, April 30th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. Sell-side analysts predict that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.